


```
E1      1    175136-87-5/RN
E2      1    175136-88-6/RN
E3      1 --> 175136-89-7/RN
E4      1    175136-90-0/RN
E5      1    175136-91-1/RN
E6      1    175136-92-2/RN
E7      1    175136-93-3/RN
E8      1    175136-94-4/RN
E9      1    175136-95-5/RN
E10     1    175136-96-6/RN
E11     1    175136-97-7/RN
E12     1    175136-98-8/RN
```

```
=> s e3
L1      1 175136-89-7/RN
```

```
=> d 11
```

```
L1  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2003 ACS
RN  175136-89-7  REGISTRY
CN  Benzenemethanamine, 2-chloro-6-phenoxy- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN  2-Aminomethyl-3-chlorodiphenyl ether
CN  2-Chloro-6-phenoxybenzylamine
FS  3D CONCORD
MF  C13 H12 Cl N O
SR  CAS Registry Services
LC  STN Files:  CA, CAPLUS, CHEMCATS, CSCHEM, USPAT2, USPATFULL
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

```
=> FIL REGISTRY
```

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.08	2.29

FILE 'REGISTRY' ENTERED AT 16:25:19 ON 01 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 MAR 2003 HIGHEST RN 501072-24-8
DICTIONARY FILE UPDATES: 31 MAR 2003 HIGHEST RN 501072-24-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

09845992

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION

FULL ESTIMATED COST

46.19	194.55
-------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

	SINCE FILE	TOTAL
	ENTRY	SESSION

CA SUBSCRIBER PRICE

-6.51	-6.51
-------	-------

STN INTERNATIONAL LOGOFF AT 09:05:22 ON 04 FEB 2003

09845992

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID: ssspta1626kas

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
 saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
 now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27 Oct 21 EVENTLINE has been reloaded
NEWS 28 Oct 24 BEILSTEIN adds new search fields
NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 31 Nov 18 DKILIT has been renamed APOLLIT
NEWS 32 Nov 25 More calculated properties added to REGISTRY
NEWS 33 Dec 02 TIBKAT will be removed from STN
NEWS 34 Dec 04 CSA files on STN
NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36 Dec 17 TOXCENTER enhanced with additional content
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN
NEWS 38 Dec 30 ISMEC no longer available
NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 40 Jan 21 NUTRACEUT offering one free connect hour in February 2003
NEWS 41 Jan 21 PHARMAML offering one free connect hour in February 2003
NEWS 42 Jan 29 Simultaneous left and right truncation added to COMPENDEX.

Kamal Saeed

09845992

ENERGY, INSPEC

| | |
|--------------|---|
| NEWS EXPRESS | January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002 |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | General Internet Information |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS PHONE | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 09:03:32 ON 04 FEB 2003

FILE 'REGISTRY' ENTERED AT 09:03:40 ON 04 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 FEB 2003 HIGHEST RN 484639-64-7
DICTIONARY FILE UPDATES: 2 FEB 2003 HIGHEST RN 484639-64-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END) :end

09845992


=>
Uploading C:\Program Files\Stnexp\Queries\0984599211.str

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> d
L2 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L2 QUE ABB=ON PLU=ON L1

=> s 11 full
FULL SEARCH INITIATED 09:04:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2182 TO ITERATE

100.0% PROCESSED 2182 ITERATIONS 33 ANSWERS
SEARCH TIME: 00.00.01

L3 33 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
148.15 148.36

FILE 'CAPLUS' ENTERED AT 09:04:23 ON 04 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available

09845992

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Feb 2003 VOL 138 ISS 6
FILE LAST UPDATED: 3 Feb 2003 (20030203/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 13
L4          10 L3
=> d ibib abs hitstr tot
```

09845992

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:925264 CAPLUS
DOCUMENT NUMBER: 138:11431
TITLE: 5-HT_{1A} antagonist or an .alpha.-adrenergic
antagonist
in combination with an serotonin reuptake inhibitor
for treatment of sleep disorders, including sleep
apnea
INVENTOR(S): Howard, Harry Ralph, Jr.
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO. KIND DATE APPLICATION NO. DATE
----- -----
EP 1262197 A2 20021204 EP 2002-253589 20020522
EP 1262197 A3 20021218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2002183306 A1 20021205 US 2002-75849 20020213
JP 2003026602 A2 20030129 JP 2002-155222 20020529
PRIORITY APPLN. INFO.: US 2001-294322P P 20010530

OTHER SOURCE(S): MARPAT 138:11431
AB The invention provides a method of treating sleep disorders, including
sleep apnea, in a mammal, including a human, by administering to the
mammal a 5-HT_{1A} antagonist or an .alpha.-adrenergic antagonist in
combination with an serotonin reuptake inhibitor (SRI) antidepressant
agent with improvement in efficacy. Also provided are pharmaceutical
comps. contg. a pharmaceutically acceptable carrier, a 5-HT_{1A} antagonist
or an .alpha.-adrenergic antagonist, and an SRI antidepressant agent.


IT 289716-94-5 289717-18-4 289717-57-3
289717-60-8 289717-61-9 289717-67-5
289717-68-6 289717-71-1 289717-72-2
444888-21-5 444888-23-7 444888-24-6
444888-49-7 477337-55-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(5-HT_{1A} antagonist or .alpha.-adrenergic antagonist in combination
with serotonin reuptake inhibitor for treatment of sleep disorders,
including sleep apnea)

RN 289716-94-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289717-18-6 CAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-57-3 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-60-8 CAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-61-9 CAPLUS


L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289717-72-2 CAPLUS
CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 444888-21-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha..alpha..trimethyl- (9CI) (CA INDEX NAME)




RN 444888-23-7 CAPLUS
CN Benzenemethanamine, 4-chloro-2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




Kamal Saeed

09845992


L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 444888-24-8 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 444888-49-7 CAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 477337-55-6 CAPLUS
CN Benzenemethanamine, 5-fluoro-2-(4-fluoro-3-methoxyphenoxy)-N-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
for use in alcoholism and alc. dependence)
RN 289716-94-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-18-6 CAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-24-4 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-57-3 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002-925263 CAPLUS
DOCUMENT NUMBER: 138:336
TITLE: Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
INVENTOR(S): Howard, Harry Ralph, Jr.
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 37 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|---|----------|
| EP 1262196 | A2 | 20021204 | EP 2002-253105 | 20020502 |
| EP 1262196 | A3 | 20021218 | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2002370975 | |
| | A2 | 20021224 | JP 2002-132804 | 20020508 |
| AU 2002040686 | A5 | 20021205 | AU 2002-40686 | 20020516 |
| CN 200216503 | A | 20021225 | CN 2002-120350 | 20020523 |

PRIORITY APPLN. INFO.: US 2001-293088P P 20010523

OTHER SOURCE(S): MARPAT 138:336

GI




AB The present invention relates to a method of treating alcoholism or alc. dependence in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with an opioid antagonist. It also relates to pharmaceutical compns. contg. a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and an opioid antagonist. An example monoamine reuptake inhibitor is I.


IT 289716-94-5 289717-18-6 289717-24-4
289717-57-3 289717-58-4 289717-60-8
289717-61-9 289717-67-5 289717-68-6
289717-71-1 289717-72-2

RU: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of a monoamine reuptake inhibitor and an opioid antagonist


L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289717-58-4 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-60-8 CAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-61-9 CAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-67-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Kamal Saeed


09845992

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
Rotation (+).




RN 289717-68-6 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-,
(-) - (9CI) (CA INDEX NAME)

Rotation (-).




RN 289717-71-1 CAPLUS
CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)



RN 289717-72-2 CAPLUS
CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002-904325 CAPLUS
DOCUMENT NUMBER: 137-380038
TITLE: Combination treatment with monoamine reuptake inhibitor and dopamine D3 receptor agonist for depression and anxiety
INVENTOR(S): Howard, Harry Ralph, Jr.
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| EP 1260221 | A2 | 20021127 | EP 2002-253135 | 20020503 |
| EP 1260221 | A3 | 20021218 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, PL, RO, MK, CY, AL, TR
AU 2002040681 | A5 | 20021205 | AU 2002-40681 | 20020516 |
| JP 2002370976 | A2 | 20021224 | JP 2002-141515 | 20020516 |
| CN 1386504 | A | 20021225 | CN 2002-120351 | 20020523 |
| PRIORITY APPLN. INFO.: | | | US 2001-293063P | F 20010523 |

OTHER SOURCE(S): MARPAT 137:380038
AB The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with a dopamine D3 receptor agonist. It also relates to pharmaceutical compns. contg. a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and a dopamine D3 receptor agonist.


IT 289716-94-5 289717-18-6 289717-24-4
289717-57-3 289717-58-6 289717-60-8

289717-61-9 289717-67-5 289717-68-6

289717-71-1 289717-72-2


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoamine reuptake inhibitor; combination treatment with monoamine reuptake inhibitor and dopamine D3 receptor agonist for depression and anxiety)

RN 289716-94-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-18-6 CAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289717-24-4 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-,
(-) - (9CI) (CA INDEX NAME)



RN 289717-57-3 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-58-4 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-,
(9CI) (CA INDEX NAME)




RN 289717-60-8 CAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)

Kamal Saeed

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
INDEX NAME)




RN 289717-61-9 CAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-67-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).




RN 289717-68-6 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).


L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
INDEX NAME)



RN 289717-71-1 CAPLUS
CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-72-2 CAPLUS
CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002-755211 CAPLUS
DOCUMENT NUMBER: 137-262839
TITLE: Preparation of phenoxybenzylamines as monoamine reuptake inhibitors for treatment of CNS disorders.
INVENTOR(S): Howard, Harry R.; Schmidt, Christopher J.; Seeger, William F.; Elliott, Mark L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S. Ser. No. 529,207.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|-------------|
| US 2002143003 | A1 | 20021003 | US 2001-845992 | 20010430 |
| WO 2000050380 | A1 | 20000831 | WO 2000-1708 | 20000202 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, BM, AZ, BY, KG, KZ, MD, RU, TJ, TW, RW: GH, GM, KE, LS, MW, SD, SI, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRIORITY APPLN. INFO.: US 1999-121313P P 19990223 | | | | |
| | | | US 2000-529207 | A2 20000202 |
| | | | WO 2000-1B108 | W 20000202 |


OTHER SOURCE(S): MARPAT 137:262839
AB ROZCR34NR1R2 [R = (un)substituted Ph; R1,R2 = H, alk(en)yl, alkynyl; NR1R2 = heterocyclic]; R3,R4 = H or (fluoro)alkyl; R3R4 = (un)substituted alkylene; R2R3 = atoms to complete a heterocyclic ring; Z = (un)substituted phenylene were prep'd as monoamine reuptake inhibitors (no data). Such compds. are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.

IT 289716-89-8P, Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl-, hydrochloride 289716-93-4P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, 289716-94-5P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, 289716-95-6P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, (2Z)-2-butenedioate (2:1) 289717-18-6P, Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-, 289717-19-7P, Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-, (2Z)-2-butenedioate (1:1) 289717-23-3P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-3-fluoro-N-methyl-, (2Z)-2-butenedioate (1:1) 289717-24-4P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- 289717-25-5P, Benzenemethanamine,

2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (2Z)-2-butenedioate (1:1) 289717-26-6P, Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, hydrochloride 289717-28-8P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-fluoro-N-methyl-, (2Z)-2-butenedioate (1:1) 289717-35-7P, Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl-,


L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
hydrochloride 289717-36-8P, Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl-, hydrochloride 289717-37-3P, Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl-, 289717-58-4P, Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, 289717-60-8P, Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl-, 289717-61-9P, Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl-, 289717-67-5P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (+)- 289717-68-6P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (-)- 289717-71-1P, Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl-, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl-, RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prep. of phenoxybenzylamines as monoamine reuptake inhibitors)

RN 289716-89-8 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289716-93-4 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 289716-94-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)

09845992

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289716-95-6 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-,
(2Z)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)
CM 1
CRN 289716-94-5
CMF C14 H12 Cl2 F N O




CM 2
CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 289717-18-6 CAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289717-19-7 CAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)
CM 1
CRN 289717-18-6
CMF C14 H12 Cl3 N O




CM 2
CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 289717-23-3 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-3-fluoro-N-methyl-,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)
CM 1
CRN 289717-22-2
CMF C14 H12 Cl2 F N O

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




CM 2
CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-24-4 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- (9CI) (CA INDEX NAME)




RN 289717-25-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 289717-24-4
CMF C15 H14 Cl2 F N O

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




CM 2
CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-26-6 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-,
hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289717-28-8 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-fluoro-N-methyl-,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 289717-27-7
CMF C14 H12 Cl2 F N O

Kamal Saeed

09845992


L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




CM 2

CRN 110-16-7
CNF C4 H4 O4

Double bond geometry as shown.




RN 289717-35-7 CAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 289717-36-8 CAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl

RN 289717-57-3 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-58-4 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- (9CI) (CA INDEX NAME)




RN 289717-60-8 CAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289717-61-9 CAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-67-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).




RN 289717-68-6 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).


L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 289717-71-1 CAPLUS
CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-72-2 CAPLUS
CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




IT 289718-10-1P, Benzamide, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- RL; RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of phenoxybenzylamines as monoamine reuptake inhibitors)

RN 289718-10-1 CAPLUS
CN Benzamide, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)

09845992

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:674788 CAPLUS
DOCUMENT NUMBER: 137:195595
TITLE: Atypical antipsychotic-antidepressant combination for treatment of depression, obsessive compulsive disorder, and psychosis
INVENTOR(S): Howard, Harry R., Jr.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|------------|
| US 2002123490 | A1 | 20020905 | US 2001-10651 | 20011206 |
| EP 1238676 | A1 | 20020911 | EP 2002-251153 | 20020220 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2002308801 | A2 | 20021023 | JP 2002-50579 | 20020227 |
| PRIORITY APPLN. INFO.: | | | US 2001-272619P | P 20010301 |
| OTHER SOURCE(S): MARPAT 137:195595 | | | | |


AB The invention provides a method for treating depression, obsessive compulsive disorder, and psychosis in a mammal, including a human, by administering to the mammal an atypical antipsychotic in combination with an antidepressant agent with improvement in efficiency. It also provides pharmaceutical compone. contg. a pharmaceutically acceptable carrier, an atypical antipsychotic, and a serotonin reuptake inhibitor.

IT 289716-94-4 289717-18-6 289717-24-4
289717-57-2 289717-58-4 289717-60-8
289717-61-3 289717-67-5 289717-68-6

289717-71-1 289717-72-2 444888-21-5
444888-23-7 444888-24-8 444888-30-6
444888-49-7


RL: PAC (pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(atypical antipsychotic-antidepressant combination for treatment of depression, obsessive compulsive disorder, and psychosis)

RN 289716-94-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-18-6 CAPLUS


L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-24-4 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-57-3 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-58-4 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 289717-60-8 CAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-61-9 CAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-67-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 289717-68-6 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).


Kamal Saeed

09845992


L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 289717-71-1 CAPLUS
CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)




RN 289717-72-2 CAPLUS
CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)




RN 444888-21-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.,.alpha.-trimethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 444888-23-7 CAPLUS
CN Benzenemethanamine, 4-chloro-2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)




RN 444888-24-8 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)





RN 444888-30-6 CAPLUS
CN Benzenemethanamine, 5-chloro-2-(3,4-dichlorophenoxy)-.alpha.-ethyl-N-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 444888-49-7 CAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:595509 CAPLUS
DOCUMENT NUMBER: 137:135106

TITLE: Combination of a 5-HT3 receptor antagonist with a serotonin reuptake inhibitor for the treatment of depression

INVENTOR(S): Howard, Harry R.

PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| US 2002107244 | A1 | 20020808 | US 2001-2303 | 20011102 |

EP 1230921 A1 20020814 EP 2002-250541 20020128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2002275097 A2 20020925 JP 2002-20186 20020129
BR 2002000246 A 20021029 BR 2002-246 20020131

PRIORITY APPLN. INFO.: US 2001-266340P P 20010202

OTHER SOURCE(S): MARPAT 137:135106

AB The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a 5-HT3 receptor antagonist in combination with a serotonin reuptake inhibitor (SRI) antidepressant agent with improvement in sexual function and/or redn. in gastro-intestinal side effects. It also relates to pharmaceutical compns. contg. a pharmaceutically acceptable carrier, a 5-HT3 receptor antagonist and an SRI antidepressant. The ratio of the 5-HT3 receptor antagonist and the SRI antidepressant agent is between 0.001 to 1 and 1000 to 1, and esp. between 0.01 to 1 and 100 to 1 (no data).

IT 289716-94-5 289717-18-6 289717-24-4

289717-57-3 289717-58-4 289717-60-8

289717-61-2 289717-67-5 289717-68-6

289717-71-1 289717-72-2 444888-21-5


444888-23-7 444888-24-8 444888-30-6

444888-49-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination of 5-HT3 receptor antagonist with serotonin reuptake inhibitor for treatment of depression)


RN 289716-94-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




Kamal Saeed

09845992


L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 289717-18-6 CAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-24-4 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- (9CI) (CA INDEX NAME)




RN 289717-57-3 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-58-4 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)


L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 289717-60-8 CAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-61-9 CAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-67-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).

Rotation (-).

RN 289717-68-6 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (-)- (9CI) (CA INDEX NAME)




RN 289717-71-1 CAPLUS
CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-72-2 CAPLUS
CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 444888-21-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.,.alpha.-trimethyl- (9CI) (CA INDEX NAME)



RN 444888-23-7 CAPLUS
CN Benzenemethanamine, 4-chloro-2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 444888-24-8 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)





Kamal Saeed

09845992

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 444888-30-6 CAPLUS
CN Benzenemethanamine, 5-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 444888-49-7 CAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:171851 CAPLUS
DOCUMENT NUMBER: 136:232110
TITLE: Preparation of phenoxybenzylamines as selective serotonin re-uptake inhibitors
INVENTOR(S): Adam, Mavis Diane; Andrews, Mark David; Elliott, Mark Leonard; Gymer, Geoffrey Edward; Hepworth, David; Howard, Harry Ralph, Jr.; Middleton, Donald Stuart; Stobie, Alan
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 110 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2002018333 | A1 | 20020307 | WO 2001-IB1521 | 20010822 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2001078650 | A5 | 20020313 | AU 2001-78650 | 20010822 |
| PRIORITY APPLN. INFO.: GB 2000-21593 A 20000831
GB 2001-7116 A 20010321
WO 2001-IB1521 W 20010822 | | | | |
| OTHER SOURCE(S): MARPAT 136:232110
GI | | | | |



AB Title compds. I [R1 and R2 independently = H, alkyl or

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
(CH₂)_n(C₁-C₆cycloalkyl) wherein n = 0, 1, 2 or 3; or R1 and R2 together with the nitrogen to which they are attached form an azetidine ring; Z or Y is -SR3 and the other Z or Y is halogen or -R3; wherein R3 = C1-4 alkyl optionally substituted with fluorine; except that R3 is not CF₃; or Z and Y are linked so that, together with the interconnecting atoms, Z and Y form a fused 5 to 7-membered carbocyclic or heterocyclic ring, and wherein

when Z and Y form a heterocyclic ring, in addn. to carbon atoms, the linkage contains one or two heteroatoms independently selected from O, S and N; R4 and R5 independently = A-X, wherein A = -CH=CH- or -(CH₂)_p- where p is 0, 1 or 2; X = H, halo, CONR6R7, SO₂NR6R7, SO₂NHC(=O)R6, OH, Cl-4alkoxy, etc; or A-X = (un)substituted 5- or 6-membered heterocyclic ring contg. 1, 2 or 3 heteroatoms selected from N, S and O; R6 and R7 independently = H, (un)substituted alkyl; or R6 and R7 together with the

N to which they are attached form a (un)substituted 4-6 membered heterocyclic ring] and there pharmaceutically acceptable salts are prep'd. Thus, II was prep'd. via substitution of 5-(aminosulfonyl)-2-fluoro-N-methylbenzamide by 2,3-dihydrobenzo[b]thiophen-5-ol with successive BF₃.cmtdot.THF catalyzed amide redn., formylation of secondary amine, and redn. II demonstrated serotonin re-uptake inhibition IC₅₀ of 4.7nM. I inhibit monoamine re-uptake and in particular exhibit activity as selective serotonin reuptake inhibitors.


IT 402910-54-7P 402910-56-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.: prepn. of serotonin re-uptake inhibitors phenoxybenzylamines)

RN 402910-54-7 CAPLUS


CN Benzenemethanamine, 5-bromo-2-[3-fluoro-4-(methylthio)phenoxy]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



• HCl

RN 402910-56-9 CAPLUS
CN Benzenemethanamine, 5-bromo-2-[3-chloro-4-(methylthio)phenoxy]-N-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Kamal Saeed


09845992

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:816609 CAPLUS
 DOCUMENT NUMBER: 135:344284
 TITLE: Process for the preparation of 2-halobenzoic acids by palladium-catalyzed regioselective halogenation of benzoic acids
 INVENTOR(S): Kodama, Hiroki; Katahira, Takeshi; Nishida, Tateki; Hino, Tomokazu; Tsubata, Kenji
 PATENT ASSIGNEE(S): Nihon Nohyaku Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 29 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2001083421 | A1 | 20011108 | WO 2001-JP3707 | 20010427 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NL, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2001052638 | AS | 20011112 | AU 2001-52638 | 20010427 |
| EP 1277726 | A1 | 20030122 | EP 2001-926032 | 20010427 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2002338516 | A2 | 20021127 | JP 2001-134049 | 20010501 |
| PRIORITY APPLN. INFO.: JP 2000-131032 A 20000428 | | | | |
| JP 2001-76073 A 20010316 | | | | |
| WO 2001-JP3707 W 20010427 | | | | |

OTHER SOURCE(S): CASREACT 135:344284; MARPAT 135:344284

GI




AB: A process for the prepn. of 2-halobenzoic acids of the general formula [I]; A is OH, OM (wherein M is an alkali metal), or NR6R7 (wherein R6 and R7 are each H, C1-6 alkyl, optionally substituted Ph, or the like); R is H,

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:283913 CAPLUS
 DOCUMENT NUMBER: 134:310974
 TITLE: Preparation of biaryl ether derivatives as monoamine reuptake inhibitors
 INVENTOR(S): Howard, Harry Ralph, Jr.; Adam, Mavis Diane
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 52 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2001027068 | A1 | 20010419 | WO 2000-IB1373 | 20000927 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NL, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, MU, TJ, TM, DB, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| BR 2000014733 | A | 20020611 | BR 2000-14733 | 20000927 |
| EP 1220831 | A1 | 20020710 | EP 2000-960916 | 20000927 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| US 6410736 | B1 | 20020625 | US 2000-692335 | 20000109 |
| NO 2002001659 | A | 20020408 | NO 2002-1659 | 20020108 |
| PRIORITY APPLN. INFO.: US 1999-159276P P 19991013 | | | | |
| US 1999-167761P P 19991129 | | | | |
| WO 2000-IB1373 W 20000927 | | | | |

OTHER SOURCE(S): MARPAT 134:310974

GI



AB: The title compds. [I; rings A and B can be replaced by naphthyl group; n, m = 1-3; R1, R2 = H, alkyl, alkenyl, etc.; NR1R2 = 4-8 membered satd. (un)substituted ring contg. 1-2 heteroatoms, including N atom to which R1 and R2 are attached; R3, R4 = H, alkyl optionally substituted with 1-3 F

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
 Cl-6 alkyl, Cl-6 alkylcarbonyl, carboxyl, Cl-12 alkoxy carbonyl, optionally substituted phenylcarbonyl, or the like; n is 0 to 4; and X is Cl, Br, or iod, or alternatively nR's may be present on benzene-constituting carbon atoms adjacent to each other and form a C3-4 alkylene or C3-4 alkenylene-fused ring.] is characterized by reacting a benzoic acid of the general formula I (X = H; A, R, n = same as above) with a halogenating agent in the presence of a Pd catalyst. This process provides regioselective halogenation under mild conditions. Thus, 0.3 g o-toluic acid, 0.5 g N-iodosuccinimide, and 11 mL DMF were added to 50 mg Pd(OAc)2 in a 50 mL glass reaction vessel and stirred at 100° for 6 h to give 92% 2-iodo-6-methylbenzoic acid with 100% regioselectivity.


IT 371771-35-6P, 2-(4-Chloro-2-methylphenoxy)-N-(1,1-dimethyl-2-methylthioethyl)-6-iodobenzamide

RL: SPN (Synthetic preparation); PREP (Preparation) (prep. of 2-halobenzoic acids by regioselective halogenation of benzoic acids in presence of palladium compd.)

RN 371771-35-6 CAPLUS

CN Benzamide, 2-(4-chloro-2-methylphenoxy)-N-[1,1-dimethyl-2-

(methylthioethyl)-6-iodo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
 atoms; CR3R4 = 4-8 membered satd. (un)substituted carbocyclic ring; NR2CR3 = 4-8 membered satd. (un)substituted ring contg. 1-2 heteroatoms, including N atom to which R2 is attached; X = (un)substituted Ph, heterocarbol, heterocycl; Y = H, halo, alkyl optionally substituted with 1-3 F atoms, etc.; Z = H, halo, alkoxy, etc.) and their pharmaceutically acceptable salts which exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders, were prep. E.g., a 3-step synthesis of I [R1 = Me; R2-R4 = H; X = 5-Ph; Z = H; Y = 3,4-C12] was given. All exemplified compds. I showed IC50 of .1toreq. 250 nM for serotonin reuptake inhibition, and IC50 of .1toreq. 1000 nM for dopamine and for norepinephrine reuptake inhibition.

IT 289717-61-9


RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prep. of biaryl ether derivs. as monoamine reuptake inhibitors)

RN 289717-61-9 CAPLUS

CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Kamal Saeed


09845992

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:608707 CAPLUS
 DOCUMENT NUMBER: 133:207665
 TITLE: Preparation of phenoxybenzylamines as monoamine
 reuptake inhibitors
 INVENTOR(S): Elliott, Mark Leonard; Howard, Harry Ralph, Jr.;
 Schmidt, Christopher Joseph; Seeger, Thomas Francis
 Pfizer Products Inc., USA
 PCT Int. Appl., 60 pp.
 CODEN: PIXAD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|------------|-----------------|----------|
| WO 2000050380 | A1 | 20000831 | WO 2000-IB108 | 20000202 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
CZ, DB, DE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN,
IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LG, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GU, ML, MR, NE, SN, TD, TG | | | | |
| EP 1154984 | A1 | 2001-01-21 | EP 2000-900785 | 20000202 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO | | | | |
| BR 2000008958 | A | 20011127 | BR 2000-8958 | 20000202 |
| US 2002143003 | A1 | 20021003 | US 2001-845992 | 20010430 |
| NO 2001004047 | A | 20011022 | NO 2001-4047 | 20010820 |
| PRIORITY APPLN. INFO.: A1 20011127 US 1999-121313P P 19990223
US 2000-529207 A2 20000202
WO 2000-IB108 W 20000202 | | | | |


OTHER SOURCE(S): MARPAT 133:207665

GI



AB R02CR3R4NR1R2 [R = (un)substituted Ph; R1,R2 = H, alk(en)yl, alkynyl; NR1R2 = heterocyclic 1, R3,R4 = H or (fluoro)alkyl; R3R4 = (un)substituted alkylene; R2R3 = atoms to complete a heterocyclic ring; Z = (un)substituted phenylene] were prepd. as monoamine reuptake inhibitors (no data). Thus, 2,5-F(F3C)C6H3CHO was arroxylated by 3,4-C12C6H3OH and


L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 289716-95-6 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-,
 (2Z)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 289716-94-5
 CMF C14 H12 Cl2 F N O




CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-18-6 CAPLUS
 CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
 the product reductively aminated by Me2NH to give title compd. I.

IT 289716-89-8P 289716-93-4P 289716-94-5P
 289717-23-3P 289717-24-4P 289717-25-5P
 289717-26-6P 289717-28-8P 289717-35-7P
 289717-36-8P 289717-57-3P 289717-58-4P
 289717-60-8P 289717-61-9P 289717-67-5P
 289717-68-6P 289717-71-1P 289717-72-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prep. of phenoxybenzylamines as monoamine reuptake inhibitors)

RN 289716-89-8 CAPLUS
 CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289716-93-4 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 289716-94-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 289717-19-7 CAPLUS
 CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 289717-18-6
 CMF C14 H12 Cl3 N O



CM 2

CRN 110-16-7
 CMF C4 H4 O4


Double bond geometry as shown.



RN 289717-23-3 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-3-fluoro-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-22-2
 CMF C14 H12 Cl2 F N O



CM 2


CRN 110-16-7

Kamal Saeed


09845992

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
CMF C4 H4 O4


Double bond geometry as shown.



RN 289717-24-4 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-
(9CI) (CA INDEX NAME)




RN 289717-25-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)
CM 1
CRN 289717-24-4
CMF C15 H14 Cl2 F N O




CM 2
CRN 110-16-7
CMF C4 H4 O4

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
Double bond geometry as shown.




RN 289717-26-6 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-,
hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 289717-28-8 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-fluoro-N-methyl-,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)
CM 1
CRN 289717-27-7
CMF C14 H12 Cl2 F N O




CM 2
CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289717-35-7 CAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl-,
hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-36-8 CAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl-,
hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-57-3 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-58-4 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-
(9CI)


L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
(CA INDEX NAME)



RN 289717-60-8 CAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-61-9 CAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-67-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-,
(+)- (9CI) (CA INDEX NAME)

Rotation (+).

Kamal Saeed


09845992

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289717-68-6 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-,
(-) - (9CI) (CA INDEX NAME)

Rotation (-).




RN 289717-71-1 CAPLUS
CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)




RN 289717-72-2 CAPLUS
CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 289718-10-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of phenoxybenzylamines as monoamine reuptake inhibitors)
RN 289718-10-1 CAPLUS
CN Benzamide, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE